BRANY and ViS Research Partnership to Streamline Feasibility Assessment for Clinical Trials
Partners take aim at the inefficient research site evaluation system
Two major players in the field of clinical research trial support services will work together to bring efficiency to the clinical trial process.
Clinical trials are necessary for the development of new medical therapies, but they have become prohibitively expensive and slow. Such trials can be badly delayed because sponsors struggle to understand the capabilities of trial centers. The agreement addresses this issue, as it couples two efficient systems to gather and process information needed for research center evaluation and study start-up.
The Biomedical Research Alliance of New York (BRANY) is one of the largest networks of clinical research sites in the US. BRANY has implemented an efficient 60 day system (SMART-Start-60) for the start-up of clinical trials at academic medical centers. Their new partner, ViS Research, offers a pioneering online research feasibility platform, which eliminates the need for the cumbersome feasibility questionnaires. The collaboration will help medical researchers by reducing their administrative burden related to these feasibility questionnaires, while providing faster and easier start-up of the clinical trials.
Kimberley Irvine, EVP of Operations for BRANY said: “BRANY has built a reputation of excellence and study start-up efficiency among institutions as well as CROs and Sponsors. Our partnership with ViS Research will enhance our ability to offer BRANY certified research sites innovative technology-based solutions to improve efficiencies in the site selection process.”
“BRANY and its affiliate sites are very well regarded and we are honored to collaborate with them,” said ViS CEO Fabio Thiers MD PhD. “Our platform highlights site strengths and delivers simpler data sharing. Together, we can reduce costs and greatly improve communications with trial planners and sponsors.”
To find the right centers, trial planners send out numerous feasibility questionnaires that are often never filled out or returned. These questionnaires are still necessary because the trial planners do not have all the necessary information about sites, investigators and locations where they operate, and when they plan the trial, information available is often inaccurate, outdated, or simply non-existent.
This partnership agreement offers a much more efficient and modern model for research site selection. ViS Research's online feasibility platform delivers the capabilities of research sites, investigators and locations where they operate. BRANY will leverage the live analytics provided by ViS Research to provide even faster and more efficient site start-up. The end result will be faster access to medical therapies for the patients who need them.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
